scispace - formally typeset
P

Paniti Sukumvanich

Researcher at University of Pittsburgh

Publications -  92
Citations -  2399

Paniti Sukumvanich is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Endometrial cancer & Radiation therapy. The author has an hindex of 25, co-authored 75 publications receiving 1965 citations. Previous affiliations of Paniti Sukumvanich include Albert Einstein College of Medicine.

Papers
More filters
Journal ArticleDOI

National Cancer Data Base Analysis of Radiation Therapy Consolidation Modality for Cervical Cancer: The Impact of New Technological Advancements

TL;DR: Consolidation brachytherapy is a critical treatment component for locally advanced cervical cancer; however, there has been declining utilization of brachyTherapy, and increased use of IMRT and SBRT boost coupled with increased mortality risk should raise concerns about utilizing these approaches over brachyotherapy.
Journal ArticleDOI

Total pelvic exenteration: The Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003)

TL;DR: Overall 5-year survival is encouraging, and modifications in surgical technique have improved the reconstructive phase, and TPE remains a potentially curative option for patients with recurrent cervix cancer and pelvic floor reconstruction.
Journal ArticleDOI

USA endometrial cancer projections to 2030: should we be concerned?

TL;DR: The projected increase of EC over next 16 years indicates the need for close monitoring of EC trends, and the best-fitting model predicting EC rates projected an increase to 42.13 EC cases per 100,000 by the year 2030.
Journal ArticleDOI

MRI-Guided High–Dose-Rate Intracavitary Brachytherapy for Treatment of Cervical Cancer: The University of Pittsburgh Experience

TL;DR: This study constitutes one of the largest reported series of MRI-guided brachytherapy in North America, demonstrating excellent local control with acceptable morbidity and may be warranted when feasible for adenocarcinomas to offset the risk of local failure.